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Abstract 
Review on CCND1, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords 
CCND1; Cell cycle 
Identity 
HGNC (Hugo): CCND1 
Location: 11q13.3 
Other names: BCL1, U21B31, D11S287E 
BCL1 (11q13) - Courtesy Mariano Rocchi. 
DNA/RNA 
Description 
Located in the long (q) arm of chromosome 11 in the 
13th band, the length of the CCND 1 gene is  
about 13.38 Kb (precisely 13,388 bases), contains 5 
exons and is arranged in a telomere to centromere 
orientation. 
Transcription 
According to Ensembl, the full length, functional 
transcript of CCND1 (Transcript ID 
ENST00000227507) is 4307 bp in length, encoding 
5 coding exons.  
From the total of 6 transcripts generated, only two 
are protein coding. 
Pseudogene 
None reported. 
Protein 
Description 
The full length CCND1 protein has a length of 295 
amino acids, having a molecular weight of 33729 
Da. CCND1 is a member of the cyclin family, Cyclin 
D subfamily and contains 1 cyclin N-terminal 
domain. 
Localisation 
Nuclear, cytoplasmic and membrane. Accumulation 
of CCND1- CDK4 complexes occur in the nuclear 
membrane, which are then transported to the nucleus 
through interactions with KIP-CIP family member 
proteins (By similarity, a LaBaer et. al.,1997). 
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The figure shows the chromosomal location of CCND1 (Red line). Image courtesy genecards.org 
 
 
 
 
 
Diagram shows the different transcripts of CCND1 (BROWN, BLUE AND MAROON BOXES). Beginning of boxes represents 
transcription start sites. Filled areas represent translated regions. The brown box representing transcript CCND- 001 forms the full 
length, active protein. Image adapted from Ensembl.org 
 
 
 
 
 
 
Schematic diagram of full length CCND1, showing different domains. Adapted from PDB P24385. 
Data origin/ Colour codes: Data in Green originates from UniProtKB.; Data in blue originates from PDB. Secstruc- Secondary 
structure projected from representative PDB entries onto the UniProt sequence. a. Red box- Helix.  b. Grey tube- Coil. Data in 
red indicates combined ranges of Homology Models from SBKB and the Protein Model Portal. 
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The RNA expression data of CCND1 based on data from BioGPS, Illumina Human BodyMap, and SAGE, with SAGE tags from 
CGAP, Figure shows RNA expression data (presence/absence) for RNA genes is according to H-InvDB, NONCODE, miRBase, 
and RNAdb. The expression images based on data from BioGPS, Illumina Human BodyMap, and SAGE, with SAGE tags from 
CGAP. BioGPS: 76 normal tissues were used and compartments hybridized against HG-U133A, with Affeymetrix MAS5 
algorithm used in array processing. Illumina body map: Transcripts were mapped to genes from 16 normal human tissues by 
sequencing. Cufflinks program was used to calculate Fragments per Kilobase of exon per Million fragments mapped (FPKM) and 
rescaled by multiplying FPKM by 100 and calculating the root. CGAP: SAGE Normal. For Serial Analysis of Gene Expression 
(SAGE) of 19 normal human tissues, Hs frequencies and Hs libraries in CGAP datasets are mined for information regarding the 
number of SAGE tags per tissue. Unigene clustering was applied to Tags, followed by a particular gene by mining Hs best gene, 
Hs best tag and Hs GeneData. The number of appearances of the corresponding tag divided by the total number of tags in 
libraries derived from that tissue was used in calculating the level of expression of a particular gene, which were then rescaled by 
making the genomic mean of all tissues equal. Intermediate between log and linear scales are normalized intensities drawn on 
root scale, with values not comparable between datasets (i.e. Microarray, RNAseq and SAGE). Figure courtesy: genecards.org. 
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Presentation of protein expression images for 35 tissues, fluids and cells. Data sources: 
MOPED - Eugene Kolker, Bioinformatics & High-throughput Analysis Lab, Seattle Children's Research Institute; PaxDb - 
Christian von Mering, Bioinformatics Group, Institute of Molecular Life Sciences, University of Zurich;  MAXQB - Matthias Mann, 
Department of Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Germany. The data was normalized 
as follows: For each sample, ppm protein values were calculated, if not provided so by data sources. For each sample from 
MAXQB, iBAQ expression values were divided by sum of values of each sample, and multiplied by 1,000,000. For all samples, 
data was gene centrically aggregated by summing expression values of all isoforms for each gene. For better visualization of 
graphs, expression values are drawn on a root scale, which is an intermediate between log and linear scales as used for our 
mRNA expression graphs (PMID 12519968). 
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Expression in tissues: Top: Cyclin D1 overexpression in keratoacanthomas (KAs) and squamous cell carcinomas (SCCs). 
CCND1 (brown), counterstain hemalaun (blue). (a) Normal skin and (b) actinic keratosis, a precursor lesion of SCCs. (c-f) 
Representative KAs (c) Higher magnification of a different tumor (d); medium expression (e); and low expression (f) of cyclin D1. 
Bar=50 micro-m. Image courtesy Burnworth et. al., 2006. Middle: The figure shows the localization of CCND1 in Ramos cells. 
Image courtesy Abcam. Bottom: Expression during cell cycle: Image shows the levels expression of CCND1 during different 
phases of the cell cycle (left panel) and the function associated in each phase (right). Image courtesy kinexux.ca (left) and Yang 
et. al., 2006 (right). 
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Function 
CCND1 binds and activates the G1 cyclin dependent 
kinases, Cdk4 and Cdk6. The complex then 
phosphorylates and inhibits members of the 
retinoblastoma (RB) family of protein including 
RB1, thereby regulating the G1/S transition in the 
cell cycle (Kato et al., 1993).  
CCND1 has a kinase-independent function of 
sequestering CDK inhibitors such as p27 Kip1 and 
p21Cip1and promoting efficient activation of Cyclin 
E/CDK2-containing complexes (Polyak et al., 1994; 
Sherr and Roberts, 1999).  
CCND1 phosphorylates Smad3 and inhibits its 
transcriptional activity and antiproliferative function 
(Matsuura et. al., 2004). 
Homology 
The CCND1 gene is conserved in chimpanzee, 
Rhesus monkey, dog, cow, mouse, rat, chicken, 
zebrafish, and frog (According to Homologene, 
NCBI). 
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Top: String model depicting probable binding partners on CCND1. Image adapted from string-db.org; Bottom: The figure shows 
the different proteins with which CCND1 interact and the different functions that result from such interactions. Picture courtesy:  
Pestell, 2013. 
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Gene tree of CCND1 Human has been encircled in red. Adapted from ensembl.org. 
 
Figure shows the predicted miRNA binding sites in the 3' UTR of CCND1. Image courtesy TargetScan 6.2. 
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Figure represents the types and percentages of various of mutations observed in CCND1. Image adapted from COSMIC gene 
analysis. 
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Figure represents the types and percentages of various of mutations observed in CCND1. Image adapted from COSMIC gene 
analysis. 
 
 
 
Mutations and copy number variations of CCND1 in different organs. Red bar: Loss. Grey bar: Gain. Adapted from COSMIC 
gene analysis. 
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Mutations 
Somatic 
CD95 somatic mutations have been reported in 
several cancers. 
Epigenetics 
CCND1 and miRNAs:  
miR365 
in Gastric cancer cell line BGC-823 Binds to 3' 
UTR of CCND1 in gastric cancer. miR-365 
markedly decreased the expression (mRNA and 
protein) of CCND1. Conversely, miR365 
knockdown repressed cell growth, which can be 
overcome by CCND1 over-expression. Similar 
inverse co-relation was obtained between miR-365 
and CCND1 expression in patient samples. (Long-
Guo et. al., 2013).  
in Vascular smooth muscle cell (VSMC)  miR-365 
suppresses CCND1 significantly in mRNA and 
protein levels in primary rat VSMC. CCND1 is a 
direct target of miR-365 in vascular smooth muscle 
cells, as shown by significant inhibition of the 
luciferase activity of wild type CCND1 3' UTR, but 
not the mutant cyclinD1 3' UTR with the mutant 
biding site of miR-365 (Zhang et. al., 2014). CCND1 
is a potential target of mir-365 through direct 
binding. (Kim et. al., 2014).  
in Colon cancer miRNA directly binds to the 3'UTR 
of CCND1, proved by luciferase reporter assay. 
Transfection of miR365 significantly decreased 
CCND1 expression in HT29 and LoVo cells. 
Pearson's co-relation between miR-365 levels and 
CCND1 expression by qRT-PCR and western blot 
showed that they were inversely correlated (Nie et. 
al., 2012).  
miR-338-3p in Hepatocyte cell line LO2  miR-338-
3p binds at two regions in the 3' UTR of CCND1( 
mainly at the site spanning nucleotides 2397-2403). 
Overexpression of miR-338-3p downregulates 
endogenous CyclinD1 protein, while inhibition 
upregulates CyclinD1 protein, without any change in 
CCND1 mRNA levels. miR-338-3p post-
transcriptionally regulates CCND1 (Fu et. al., 2012).  
miR-19a in Human umbilical vein endothelial 
cells (HUVECs)  miR-19a binding site (nucleotides 
1,778-1,785 in human CCND1) identified by 
sequence alignment, which is highly conserved 
among different species. Binding of miR-19a to 3' 
UTR of CCND1 verified by luciferase assay. 
CCND1 protein expression markedly reduced upon 
over-expression  of miR-19a, although no change in 
RNA expression. miR-19a post-transcriptionally 
regulates CCND1 expression (Qin et. al., 2010).  
miR-490-3p in A549 Lung cancer cell line  miR-
490-3p binds to 3' UTR of CCND1. Over-expression 
decreased the expression of CCND1, both at the 
RNA and protein levels (Gu et. al., 2014).  
miR-302 in Endometrial cell line Ishikawa  
Directly targets CCND1 and significantly inhibited 
protein expression (Yan et. al., 2014).  
miR-449-a in Gastric cancer cell line SGC7901 
miR-449a inhibited SGC7901 cells proliferation and 
enhanced cisplatin chemosensitivity by 
downregulating expression of CCND1, respectively, 
via directly targeting the 3'-untranslated regions of 
CCND1 mRNA (Hu et. al., 2014).  
miR-16 in Bladder cancer cell line TCHu-1 
Binding of miR16 to 3' UTR of CCND1 and its 
reduced expression was validated by luciferase 
assay, while the reverse result was obtained by 
mutation of the conserved miR-16 binding motif. 
Overexpression of miR-16 in TCHu-1 cells led to 
reduced CCND1 protein expression, whereas its 
inhibition led to an increased expression of CCND1 
(Jiang et. al., 2013).  
miR-9 in Gastric cancer Databases indicated 
potential binding site of miR-9 with high 
complementarity at CCND1 39-UTR (bases 2974-
2995), which was validated by luciferase reporter 
assay. Significant inverse correlation between miR-
9 expression and CCND1 transcript levels in gastric 
cancer tissues and cell lines. Overexpression of 
miR9 in gastric cancer cell lines SGC-7901 and AGS 
resulted in reduced RNA and protein expression of 
CCND1, whereas knockdown of miR-9 produced 
the opposite result, proving that miR-9 considerably 
inhibited the expression of CCND1 through post-
transcriptional repression. Results validated by in-
vitro experiments (Zheng et. al., 2013).  
miR-195 in Glioma  Analysis using publicly 
available algorithms (TargetScan, Pictar, 
miRANDA) indicates that CCND1 is a predicted 
target of miR-195, which was validated by 
overexpression of miR- 195, which reduced, but 
inhibition of miR-195 increased, the luciferase 
activity of CCND1-39UTR in a consistent and dose-
dependent manner. Upregulation of miR-195 
decreased, but inhibition of miR-195 increased, the 
expression levels of CCND1 in LN18 and T98G 
glioma cells. The findings were also validated in a 
model system in mice (Hui et. al., 2013).  
miR-155 in  Human extravillous trophoblast 
derived HTR-8/SVneo cells  Bioinformatics 
analysis showed that, at the 3' untranslated region 
(UTR) of CCND1, six bases are complementary to 
the seed region of miR-155. Luciferase assays and 
CCND1 3'UTR transfection assays validated that 
CCND1 3'UTR was the target of miR-155 in HTR-
8/SVneo cells. Overexpression of miR-155 in HTR-
8/SVneo cells reduced the level of CCND1 protein 
(Dai et. al., 2012).  
miR-143 in Mesenchymal stem cells from the 
bone marrow of male Fischer 344 rats Ectopic 
expression of miR-143 also increased CCND1 in the 
native MSC as compared with scramble transfected 
cells .On the contrary, pre-treatment of AAMSC 
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with miR-143 specific antagomir significantly 
abolished CCND1 expression (Lai et. al., 2012).  
miR-21  
in Mouse liver regeneration Cyclin D expression 
and G1 phase transition of hepatocytes after 2/3 PH 
depend on induced miR-21 expression. Knockdown 
of miR-21 impaired progression of hepatocytes into 
S phase of the cell cycle, mainly  through a decrease 
in levels of cyclinD1 protein, but not Ccnd1 mRNA, 
whereas increased miR-21 expression facilitated 
CCND1 translation in the early phase of liver 
regeneration (Ng et. al., 2012).  
in Renal cancer miR-21 controlled the expression of 
CCND1 through NFkB-dependent transcription and 
mediated renal cancer cell proliferation by CCND1 
(Bera et. al., 2013).  
miR-520-b in Hepatoma cell lines miR520-b 
directly targets the 3 'UTR of CCND1; proved by 
dual luciferase reporter system. Down-regulation of 
protein levels of CCND1 occurred on over-
expression of miR520-b in HepG2 and H7402 cells, 
while the over-expression occurred on inhibition in 
miR520-b. Tumors in mice over-expressing 
miR520-b also showed lower CCND1 expression 
(Zhang et. al., 2012).  
miR-193b in Melanoma TargetScan showed that 
miR193b binds to the 3'UTR of CCND1, which was 
proved by luciferase reporter assay. miR-193b over-
expression led to nearly 50% reduction in CCND1 
mRNA and protein levels in Malme-3M cells than in 
control (Chen et. al., 2010).  
miR-17/20 in Breast cancer Levels of the miR-17-
5p/miR-20a miRNA cluster were inversely 
correlated to CCND1 abundance in human breast 
tumors and cell lines. miR 17/20 negatively regulates 
the expression of CCND1 by binding to a conserved 
3'UTR region (nucleotides 2,109-2,117) of the gene 
(Yu et. al., 2008).  
miR-20 and miR106-a in Spermatogonial stem 
cells (SCC) They promote renewal at the post-
transcriptional level via targeting CCND1. 
Knockdown of CCND1 results in renewal of SCCs 
(He et. al., 2013).  
miR-503 in Endometrioid endometrial cancer 
(EEC) Binds to 5' UTR of CCND1 and its 
expression is inversely co-related with CCND1 in 
EEC tissues and cell lines (Xu et. al., 2013).  
miR-449b in SW116 colon cancer stem cell 
Transfecting pre-miR-449b and inhibiting miR-449b 
altered protein expression levels of CCND1 (Fang, 
2013).  
miR-15a and miR16-1 in Osteosarcoma They bind 
to 3'-UTR of CCND1 and suppress transcription of 
CCND1 (Cai et. al., 2012).  
miR-138 in Nasopharyngeal carcinoma CCND1 is 
a novel direct target of miR138. mRNA levels of 
CCND1 were inversely correlated with miR-138 
expression (Liu et. al., 2012).  
miR-34a in A549 cell line Ectopic expression of 
miR-34a reduces both mRNA and protein levels of 
CCND1 by targeting the 3'-untranslated mRNA 
region of CCND1 (Sun et. al., 2008).  
miR-29a in Breast cancer cell lines Over-
expression of miR29a down-regulation of CCND1 
expression in  MDA-MB-453 cells, whereas  in 
MCF-10A cells with Mir-29a knockdown, CCND1 
was up-regulated (Wu et. al., 2013).  
miR-7 in Colorectal cancer cell lines Over-
expression of miR-7 significantly decreased CCND1 
expression (Xu et. al., 2014).  
miR-545 in Lung cancer miR-545 caused cell cycle 
arrest at the G0/G1 phase and induced cell apoptosis 
in lung cancer cells by targeting CCND1. The effects 
of CCND1 down-regulated by miR-545 were similar 
to those caused by siRNAs of CCND1  and over-
expression of CCND1 could abolish the miR-545-
induced inhibition of cell proliferation (Du et. al., 
2014).  
miR-125b in Melanoma Cells over-expressing 
miR-125b exhibited reduced expression of CCND1 
(Nyholm et. al., 2014).  
miR-147 in Colon and lung cancer cells. 
Transfection of miR147 led to down-regulation of 
CCND1 (Lee et. al., 2014). 
Implicated in 
t(11;14)(q13;q32)/B-cell malignancies 
CCND1/ IgH 
Disease 
The t(11;14) is mainly found in mantle cell 
lymphoma; also in: B-prolymphocytic leukaemia, 
plasma cell leukaemia, splenic lymphoma with 
villous lymphocytes; rarely in: chronic lymphocytic 
leukaemia, multiple myeloma 
Prognosis 
according to the disease. 
Cytogenetics 
Complex karyotypes. 
Hybrid/Mutated gene 
5' CCND1 translocated on chromosome 14 near JH 
(junctions genes of IgH) and C in 3'. 
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Fluorescence in situ hybridization (FISH) for identification of t(11;14)(q13;q32) chromosomal translocation in metaphase nuclei. 
Orange probe represents CCND1 (chromosome 11q13), green represents IGH (chromosome 14q32). Fusion signals 
representing translocations are encircled in white. Image courtesy Ghielmini et. al., 2009. 
 
Abnormal protein 
no fusion protein, but promoter exchange; the 
immunoglobulin gene enhancer stimulates the 
expression of CCND1. 
Oncogenesis 
Overexpression of CCND1 accelerates the cell 
transit through the G1 phase (Williams et. al., 1993, 
Williams et. al., 1994, Rimokh et. al., 1994, 
Wlodarska et. al., 1994, de Boer et. al., 1997, 
Stilgenbauer et. al., 1998, Donnellan et. al., 1998, Li 
et. al., 1999, Wlodarska et. al., 2004, Sander et. al., 
2008). 
t(11;19)(q13;p13) CCND1/ FSTL3 
Found in a case of chronic lymphocytic leukaemia 
(Hayette et al., 1998). 
Acute Lymphoblastic Leukemia (ALL) 
Routinely used ALL drugs: Routinely used drugs 
failed to bind to CCND1 in in vitro docking studies 
(Jayaraman et. al., 2014). 
Adrenocortical tumors (AC) 
CCND1 was over-expression in 31.0% (13/42) in 
AC tumors compared to 17.5 % (4/23) in normal 
adrenal samples.  Similarly, mRNA of CCND1 was 
significantly over-expressed in AC compared to 
normal samples (Mitsui et. al., 2014). 
B cell neoplasia 
Strong CCND1 mRNA over-expression was 
detected in mantle cell lymphomas (23 of 23), hairy 
cell leukemias (5 of 19), and multiple myelomas (7 
of 23) with particularly high levels in 2 of the latter 
cases. Intermediate CCND1 transcripts were 
detected in multiple myeloma (5 / 23), hairy cell 
leukemia (7 / 19) Low of no CCND1 was detected in 
B -cell chronic lymphocytic leukemias (10 / 10), 
follicular lymphomas (9 / 9), mucosa associated 
lymphoid tissue lymphomas (5 / 5) and reactive 
lymphoid tissues (Specht et. al., 2002). 
Biliary Intraepithelial Neoplasia 
(BilIN) / Pancreatic Intraepithelial 
Neoplasia (PanIN) 
Immunohistochemical expression of CCND1 was 
absent or focal in nonneoplastic epithelium of the 
bile ducts and the pancreatic ducts, and were 
occasionally observed in BilIN-1 and PanIN-1 and 
more frequently in BilIN-2/3 and PanIN-2/3.  No 
significant difference was obtained between 
expression of BilIN and PanIN in semi-quantitative 
analysis (Sato et. al., 2014).  
Bladder cancer tumors 
Increased CCND1 levels were not correlated with 
OS with a pooled HR estimate, but were 
significantly correlated with progression-free 
survival (Ren et. al., 2014). Over-expression of Pin 
X1 in T24 cells leads to greater than 2 fold increase 
in mRNA expression of CCND1 than in control cell, 
with similar results obtained by Western blotting. A 
significant correlation between the immune-
histochemical expression of PinX1 and CCND1 was 
also observed in the UCB tissues (Liu et. al., 2013). 
Ursane triterpenoid isopropyl 3-hydroxyurs-12-en-
28-oat (UA17) (Natural compound): Protein level of 
CCND1 was down-regulated in a dose-dependent 
manner when treated with UA17or Cisplatin in 
NTUB1 cells. Enhanced decrease of level of CCND1 
when treated with a combination of Cisplatin + 
UA17 (Lin et. al., 2014) Metformin: Treatment with 
metformin leads to reduction in expression of 
CCND1 in a dose-dependent manner. Metformin 
treatment also markedly reduced the expression of 
CCND1 in Human Bladder Tumor Xenografts in 
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Nude Mice compared to control (Zhang et. al., 
2013). 
Breast cancer 
CCND1 induction of Dicer coordinates microRNA 
biogenesis by its transcriptional targeting (Yu et. al., 
2013). CCND1 overexpression is associated with 
longer DSS, but not recurrence-free survival, in 
patients with breast cancer (Chung et. al., 2014). 
There was a statistically significant reverse 
relationship of CCND1 with tumor grade and both 
ER and PR hormone receptors (Mohammadizadeh 
et. al., 2013). CCND1 was one of the most frequently 
altered genes in breast cancer (Wheler et. al., 2014). 
Activation of Notch-1 signaling up-regulated 
expression of CCND1 through NF-kB (Li et. al., 
2014). Acylglycerol kinase (AGK) over-expression 
led to concurrent increase in levels of CCND1 
(Wang et. al., 2014). Over-expression led to 
blockade of CCND1 expression via BCAS2 and 
beta-catenin (Sengupta et. al., 2014). Enhanced 
expression of Vav1 led to the elevation of CCND1 
and the progression of cell cycle (Du et. al., 2014). 
CCND1 was frequently more positive in ER alpha 
positive and Bmi1 positive breast tumors than ER 
alpha negative and Bmi1 negative groups (Wang et. 
al., 2014). Progesterone induced the assembly of a 
transcriptional complex among AP-1, Stat3, PR, and 
ErbB-2 at the CCND1 promoter, which functions as 
an enhanceosome to drive breast cancer growth 
(Flaqué et. al., 2013). Prolactin-induced protein 
(PIP) silenced cells showed marked decrease in 
CCND1 expression (Naderi et. al., 2014). Calcitriol 
(Natural compound): In calcitriol-treated cells, the 
presence of antiestrogen ICI-182 down-regulated 
CCND1 gene expression (Martinez et. al., 2014). 
Euginol (Natural compound): Treatment of euginol 
decreased CCND1 level 3 fold in MDA-MB-231 
cells and 20 fold in MCF7 cells compared to control 
(Sharif et. al., 2013). Fangchinoline (Fan) (Natural 
compound): Fan decreased the expression of 
CCND1 both in the RNA and protein level (Wang et. 
al., 2014). Gallotannin (Natural compound): 
Nanostring and qPCR data showed that CCND1 was 
exclusively downregulated on treatment with 
gallotannin in triple negative breast cancer (Zhao et. 
al., 2014). 8-bromo-7-methoxychrysin (BrMC) 
(Natural compound): BrMC caused a 
dose-dependent reduction of CCND1 in HER2/neu 
over-expressing breast cancer cells (Cao et. al., 
2014). Panepoxydone (Natural compound): CCND1 
was down-regulated by dose-dependent treatment of 
Panepoxydone (Arora et. al., 2014). Thymus 
caramanicus extract (TCE) (Natural compound): 
TCE led to reduction in expression of CCND1, either 
alone or in combination with Vincristine (Mahani et. 
al., 2014). Tea polyphenols (Natural compound): 
Tea polyphenols did not significantly alter the 
expression of CCND1 in breast cancer cell lines 
(Chen et. al., 2014). Fenofibrate: Fenofibrate 
decreased the expression of CCND1 in a time and 
dose dependent manner in Triple negative breast 
cancer cells (Li et. al., 2014). Obatoclax analog SC-
2001: SC-2001 down-regulated CCND1 in TNBC 
cell lines in a dose- dependent manner (Liu et. al., 
2014). 
Chronic Myeloid Leukemia tumors 
(CML) 
Resveratrol (Res) (Natural compound): Res reduced 
expression of CCND1 in K562 cells (Siu et. al., 
2014). Quercetin (Natural compound): CML KBM7 
Cells demonstrated reduction in expression on 
CCND1 on treatment with quercetin ((Li et. al., 
2014). 
Colorectal cancer 
There was significant association between post-
menopausal hormone therapy (HRT) and CCND1 
negative-tumors, as well as significantly increased 
risk in CCND1 positive tumours (Brändstedt et. al., 
2014). High height and weight was associated with 
risk of CCND1 positive CRC in women. Increased 
hip circumference, high BMI, high WHR and high 
waist circumference was associated with CCND1 
positive tumours in men (Brändstedt et. al., 2013). 
CCND1 over-expression was significantly 
associated with both poor OS, DFS, relatively older 
patients (over 60 years), T3,4 tumor invasion, N 
positive and distant metastasis (Li et. al., 2104). 
Galectin-3 knockdown decreased the mRNA 
expression level of CCND1, whereas epirubicin 
significantly up-regulated their expression. 
Combined treatment effectively reduced the mRNA 
expression of CCND1 (Lee et. al., 2013). HMGCR 
expression was significantly associated with 
expression of CCND1 (Bengtsson et. al., 2014). 
CoCl2: Treatment of COCl2 leads to dose-dependent 
decrease in expression of CCND1 and cell cycle 
arrest (Lopez-Sanchez et. al., 2014). SW620-S and 
TGF-b1: Fibroblasts induced by Colorectal cancer 
cells, treated with SW620-S and TGF-b-1 separately 
showed high expression of CCND1 (Rao et. al., 
2014). 
Diffuse large B-cell lymphoma 
A case of diffuse large B-cell lymphoma was 
described, which developed within a rectal tubular 
adenoma with low-graded dysplasia. The mass 
showed positive staining of CCND1 (Genovese et. 
al., 2014). 
Esophageal cancer 
CCND1 G870A polymorphism had no significant 
association with esophageal squamous cell 
carcinoma (ESCC) or esophageal adenocarcinoma 
(EADC) in Caucasian or the Asian populations. 
However, the comparison of A vs. G in CCND1 
G870A showed significant differential susceptibility 
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to esophageal cancer, suggesting that the CCND1 
G870A polymorphism has no association with 
esophageal cancer risk in ethnicity and histology, 
respectively (He et. al., 2013). No significantly 
statistical differences between the two groups were 
observed in distribution of genotypes or alleles at 
CCND1 807 (Jang et. al., 2013). 
Fibrosarcoma 
KIOM-C (Natural compound): Treatment of 
HT1080 human fibrosarcoma cells led to down-
regulated expression of CCND1 compared to control 
(Kim et. al., 2014). 
Gastric cancer 
Down regulation of CCND1 by ShCCND1 in NCI-
N87 cells showed significant inhibition of cell 
proliferation, cell motility, clonogenicity, G1 arrest 
and apoptosis. Results were validated by in vivo 
studies in mice, suggesting the possibility of 
developing new gastric cancer therapies using 
lentivirus-mediated shRNA (Seo et. al., 2014). Odd-
skipped related 1 (OSR1) suppressed the expression 
of CCND1 (Otani et. al., 2014). Knockdown of P115 
led to reduction in expression of CCND1, whereas 
its over-expression led to up-regulation of CCND1 
(Li et. al., 2013). Caudatin 3-O-D-cymaropyranosyl-
(1 4)--D-oleandropyranosyl-(1 4)--D-
cymaropyranosyl-(1 4) -D-cymaropyranoside 
(CGII) (Drug): CGII induced down-regulation of 
expression of CCND1 in a dose-dependent manner 
in Gastric Cancer SGC-7901 Cells (Wang et. al., 
2013) Tetramethypyrazine (TMP) (Natural 
compound): Expression of CCND1 gradually 
decreased with increasing concentrations of TMP in 
Gastric cancer 7901 cells (Ji et. al., 2014). 
Resveratrol (Res) (Natural compound): Res reduced 
expression of CCND1 (Yang et. al., 2013). 
Glioma 
Expression of Alpha enolase (ENO-1) inhibited the 
expression of CCND1 (Song et. al., 2014). 
Hairy Cell Leukemia 
CCND1 displayed nuclear staining at variable 
intensities but with high specificity and accuracy in 
HCL biopsies, thus representing it as a valuable tool 
in the differential diagnosis of HCL and its mimics 
(Toth-Liptak et. al., 2014). 
Head and neck squamous cell 
carcinoma tumors 
Amplification, over-expression and translocation of 
CCND1 has been reported (Akervall et. al., 1997, 
Akervall et. al., 2002, Utikal et. al., 2005, Sabbir et. 
al., 2006). However, expression of CCND1 did not 
change in post-therapy tumors compared to pre-
therapy (Sarkar et. al., 2014). 
Hepatocellular Carcinoma 
CCND1 Ectopic expression of miR-184 led to down-
regulation of the SOX7 protein, resulting in up-
regulation of CCND1, cell proliferation and 
tumorigenesis (Wu et. al., 2014). SOX7-
overexpression inhibited cell growth by down-
regulating CCND1, which could be over-ridden by 
ectopic expression of CCND1 and induction of 
SOX7. Over-expression of SOX7 suppressed tumor 
formation with down-regulation of CCND1 in vivo 
(Wang et. al., 2014). Knockdown of TRIM24 led to 
decreased CCND1 expression (Liu et. al., 2014). 
KIF14 knockdown suppresses tumor cell growth 
through decrease in levels of cyclins including 
CCND1 (Xu et. al., 2014). Knockdown of 
expression of SHC SH2-domain binding protein 1 
(SHCBP1) led to reduction in expression of CCND1 
(Tao et. al., 2013). 7. 3, 3'-Di-O-methyl ellagic 
acid-4'-O-d-xylopyranoside (JNE2). JNE2 induced 
down-regulation of expression of CCND1 in HepG2 
cells (Zhang et. al., 2014). Silybin (SIL) (Natural 
compound): Treatment of HepG2 cells with SIL led 
to down-regulation of expression of CCND1 (Zhang 
et. al., 2013). SL1122-37: SL1122-37 induced down-
regulation of expression of CCND1 in PLC/ PRF/5 
HCC cells (Qin et. al., 2013). IBN-65 (1-benzyl-2-
phenyl-3-(4-isopropyl)-benzyl-imidazolium 
chloride) : IBN-65 decreased levels of CCND1 in 
Huh7 cells in Mouse model of HCC (Gopalan et. al., 
2014). Sorafenib and YC-1 : Treatment with the 
sorafenib and YC-1 combination led to a significant 
reduction in CCND1 (Kong et. al., 2014). 
Hepatoma 
Over-expression of HA-FHIT inhibited the 
expression of CCND1 in the cells. In HepG2 cells 
which were transfected with a full-length CCND1 
promoter-luciferase reporter, cotransfection with 
increasing quantities of FHIT plasmid DNA caused 
a concentration-dependent inhibition of the 
transcriptional activity of the CCND1 promoter (Ge 
et. al., 2014). 
Lung Cancer 
PAX6 down-regulation led to reduction in protein 
levels of CCND1 (Zhao et. al., 2014). Over-
expression of Ubiquitin- conjugating enzyme E2C 
(UBE2C) increased expression of CCND1 in L-78 
and SC-1680 cells, as well as in tumor transplants in 
nude mice (Tang et. al., 2014). Met- F-AEA in 
combination with URB597 induced down-regulation 
of CCND1 and subsequent G0/ G1 cell cycle arrest 
(Ravi et. al., 2014). Up-regulation of decorin led to 
significant decrease in expression of CCND1 (Liang 
et. al., 2013). The expression of CCND1 was 
significantly decreased upon knockdown of Claudin-
2 in lung adenocarcinoma (Ikari et. al., 2014). 
Knockdown of JAM-A decreased protein levels of 
CCND1 (Zhang et. al., 2013). Tea polyphenols 
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(Natural compound): Epigallocatechin gallate, 
epicatechin gallate and theaflavin reduced the 
expression of CCND1 in benzo(a)pyrene-induced 
lung carcinogenesis in mice (Manna et al., 2009).  
Polydatin: PD suppressed expression of CCND1 in 
A549 and NCI-H1975 lung cancer cell lines (Zhang 
et. al., 2014). 
Mantle Cell Lymphoma 
Decrease in expression of CCND1 by RNSi induced 
partial inhibition and reduced expression of AKT 
and/or S6, which may in turn lead to decrease in 
NOXA mRNA levels (Dengler et. al., 2014). 85% 
were weakly positive and 15%, moderately positive 
with labelled streptavidin biotin, whereas 75% were 
weakly positive and 25% moderately positive for 
CCND1 with EnVision. All 20 mantle cell 
lymphoma cases were strongly CCN D1 positive 
with catalyzed signal amplification. No evidence of 
CCND1 immunostaining was obtained in any of the 
small lymphocytic lymphoma and follicular centre 
cell lymphoma instances with any of the three 
methods used (Barranco et. al., 2003). CCND1 
showed exclusive nuclear staining and directly 
compared with the expression observed by 
immunoblot analysis with the same antibody, as well 
as with mRNA expression and with the occurrence 
of genomic rearrangements within the B CL-1 locus. 
12/13 MCL showed over-expression by 
immunohistochemistry or immunoblot, with similar 
results for additional 13 MCLs, indicating its 
importance for routine diagnostic purposes (Boer et. 
al., 2014). CCND1 mRNA could be detected in 23 
of 24 mantle-cell lymphomas by reverse 
transcription polymerase chain reaction (RT-PCR) 
whereas only 9 of 24 demonstrated a t(11;14) by 
PCR (Aguilera et. al., 1998). In 16 of 21 cases of 
MCL with overt disease, the ratio of CCND1 mRNA 
to 2-microglobulin mRNA was increased, but all 21 
cases showed increased ratios of CCND1 mRNA to 
CD19 mRNA (Howe et. al., 2004) 
Melanoma 
Piperine (Natural compound): Piperine induced 
reduction in expression of CCND1 in a dose- 
dependent manner in SK MEL 28 and B16 F0 
melanoma cells (Fofaria et. al., 2014). 
Multiple myeloma 
CCND1 expression was observed in 57% cases. 
CCND1 positive group had significantly lower 
hemoglobin level than CCND1 negative group, 
though both groups showed no statistical 
significance in regard to age, gender, Durie and 
Salmon stage, lytic bone lesions, light chain 
phenotype, creatinine, calcium, lactate 
dehydrogenase, leukocyte and platelet count and 
bone marrow histology (Padhi et. al., 2013). 
Nasopharyngeal cancer 
No significant association was found between 
CCND1 G870A polymorphism and nasopharyngeal 
carcinoma risk in total population meta-analysis. In 
the subgroup meta-analysis by ethnicity, a negative 
association was shown in Caucasian subgroup, and 
no significant association in any genetic models 
among Asians was observed (Li et. al., 2013). 
Indole-3-carbinol (I3C) : I3C induced G1 arrest by 
decreasing CCND1 expression (Chen et. al., 2013). 
Neuroblastoma 
CCND1 showed strong nuclear reactivity in a case 
study on Primary localized congenital 
sacrococcygeal neuroblastomas (SCNs) 
(Khandeparkar et. al., 2013). Over-expression of n-
myc downstream regulated gene 2 (NDRG2) 
induced down-regulation of expression of CCND1 
(Zhang et. al., 2014). A negative co-relation existed 
between WWOX and CCND1 expression 
(Nowakowska et. al., 2014) 
Odontogenic tumors 
Using immune-labelling of CCND1, no statistical 
difference was observed between primary and 
recurrent KOT (keratocystic odontogenic tumors), 
sporadic and NBCCS-KOT (nevoid basal cell 
carcinoma syndrome), and unicystic and solid AB 
(ameloblastomas) (Gurgel et. al., 2014). 
Oral cancer 
Expression of CCND1 in group 3 (leukoplakias 
exhibiting dysplasias) was significantly higher than 
in group 1 (normal buccal mucosa without any 
habits) and 2 (clinically normal mucosa from 
tobacco habits), expression in group 2 was 
significantly higher than in group and were 
statistically significant.  
CCND1 was mostly expressed in the lower third of 
epithelium. Highest expression was obtained in mild 
dysplasias, with expression consistently correlating 
with basilar hyperplasia among atypical 
morphological features (Ramakrishna et. al., 2013). 
Clinico-pathological correlation showed that 
CCND1 over-expression was related to increase in 
tumor size, tumor differentiation and higher clinical 
stages and lymph node metastasis and adversely 
affected overall survival (Zhao et. al., 2014). HPV-
negative patients, heavy alcohol consumption was 
significantly associated with somatic copy-number 
alterations (SCNAs) in CCND1 (Urashima et. al., 
2013).  
The proportions of positive staining in well, 
moderately and poorly differentiated laryngeal SCC 
were 50, 66.7, 100%, respectively, for CCND1, and 
were statistically significant, with the expression 
being positively correlated with Ang-2 expression. 
Tumor grading and CCND1 were independent 
factors affecting laryngeal SCC patient survival by 
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the Cox regression model of risk factors proportion 
analysis, which may possess clinical significance in 
evaluating the prognosis and guiding the clinical 
treatment of SCC (Liu et. al., 2013). Knockdown of 
Nemo-like kinases (NLK) led to significant 
reduction in the levels of CCND1 (Dong et. al., 
2013). 2,4-bis (p-hydroxyphenyl)-2-butenal : HPB 
242 significantly decreased CCND1 expression in 
HN22 and HSC4 Oral squamous cell carcinoma cell 
lines (Chae et. al., 2014). 
Osteosarcoma 
Selective inhibition of Ether à go-go 1 (Eag1) led to 
significant decrease in expression of CCND1 (Wu et. 
al. 2014). 
Ovarian serous carcinoma 
Compared with NOT (Normal Ovarian Tissue), 
CCND1 expression in the OSA (ovarian serous 
cystadenomas) and OSC (Ovarian serous carcinoma) 
groups was significantly elevated. Expression of 
CCND1 was positively associated with lymphatic 
metastasis and the expression gradually increased in 
the NOT, OSA, OS-BT and OSC groups and was 
associated with tumor metastasis (Song et. al., 2014). 
Pancreatic cancer 
Silencing of Frizzled (Fz)2 by siRNA or shRNA 
induced significant reduction of expression on 
CCND1 (Tomizawa et. al., 2014). Down-regulation 
of miR-196a led to decrease in expression of 
CCND1 via Nuclear Factor Kappa-B-Inhibitor 
Alpha (Huang et. al., 2014). Diallyl trisulfide 
(DATS) (Natural compound): DATS reduced levels 
of CCND1 and DATS-induced apoptosis was 
correlated with down-regulation of CCND1 protein 
levels in Capan-2 cells (Ma et. al., 2014).  
alpha-Mangostin (Natural compound): alpha--
Mangostin led to decrease in expression of CCND1 
(Xu et. al., 2014). Pristimerin (PM) : PM treatment 
produced decreased expression of CCND1 in 
MiaPaCa-2 and Panc-1 cells (Deeb et. al., 2014). 
Plasmacytoma 
A solitary plasmacytoma following complete 
remission from an intravascular large B-cell 
lymphoma, stained strongly for CCND1 while the 
initial tumor was negative for CCND1, proving 
different clonal origins of the tumors (Lee et. al., 
2014). 
Prostate cancer 
CNCD1 staining was positive (expression in .5% of 
tumor cells) in 64 cases (75.4%) and negative 
(expression in 5% of tumor cells) in 21 cases 
(including 15 cases with no immunostaining) with 
normal prostate tissues being negative for CCND1. 
Patients with high grade Gleason score and 
perineural invasion showed significant association 
with CCND1 expression, but not with PSA levels or 
other parameters. Thus, high CCND1 expression 
could be a potential marker for tumor aggressiveness 
(Pereira et. al., 2014). Univariate analyses showed 
that lymph node positivity, surgical margin 
positivity, non-localized tumor, age at prostatectomy 
and CCND1 in malignant epithelium were 
significantly associated with time to BF 
(Biochemical failure) (Rizzardi et. al., 2014). 
Reevesioside A (Natural compound): Reevesioside 
A inhibited expression of CCND1 in Hormone-
Refractory Prostate Cancers (Leu et. al., 2014). 
Scoparone (Natural compound): Scoparone 
suppressed the transcription of STAT3 target 
CCND1 in DU-145 cells (Kim et. al., 2013). 
Triptolide (Natural compound): Triptolide induced 
significant decrease of expression of CCND1 
through EZH2 (Tamgue et. al., 2014). Pifithrin 
(PFT) : Combination therapy with suboptimal doses 
of PFT-m and HT decreased expression of CCND1 
(Sekihara et. al., 2013). 
Renal cancer 
Microvessicles: CCND1 protein expression in tumor 
tissues was markedly up-regulated by MVs released 
from human Wharton's jelly mesenchymal stem cells 
(hWJ-MSCs) (Du et. al., 2014). 
Sarcoma 
Tea polyphenol epigallocatechin gallate (EGCG) did 
not alter expression of CCND1 in Sarcoma180 cells 
in vivo (Manna et. al., 2006) 
T-cell Acute Lymphoblastic Leukemia 
Resveratrol (Res) (Natural compound): Expression 
of CCND1 was attenuated in Res treated T-ALL 
CEM-C1-15 cells (Ge et. al., 2013). 
Uterine cervical cancer 
Bcl-1/Cyclin D1 alterations are associated with the 
development of uterine cervical carcinoma (Singh et. 
al., 2005). 
Various cancers 
Ursolic acid (UA) (Natural compound): UA in 
combination with other drugs led to down-regulation 
of expression of CCND1 (Doudican et. al., 2014). 
Salinomycin-: Salinomycin induced lowering of 
expression of CCND1 in Breast and prostate cancer 
cells (Lu et. al., 2014). 
Non-cancerous tissues 
Primary human cardiomyocytes:  Thrombin time-
dependently up-regulated CCND1 expression, with 
a significant response within 36-48 h (Chien et. al., 
2014).  
Human diploid fibroblast (HDFs):  CCND1 gene 
was significantly up-regulated in irradiated (1 Gy) 
HDFs as compared to untreated control, while 
bothHDFs treated with Gelam honey and irradiated 
HDFs pre-treated with Gelam honey showed down- 
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regulation of cyclin D1 gene as compared to 
irradiated HDFs. HDFs treated with Gelam honey 
during radiation and post-irradiation however 
showed significant up-regulation of cyclin D1 gene 
as compared to untreated control (Ahmed et. al., 
2014).  
Human coronary artery smooth muscle cells 
(HCASMCs):  FABP4 induced increase in 
expression of the downstream genes CCND1 
(Girona et. al., 2013).  
Vascular smooth muscle cells:  STS (sodium 
tanshinone IIA silate) decreased the expression of 
cell cycle-associated protein, CCND1 (Wu et. al., 
2014). PDGF-induced CCND1 mRNA and protein 
expression was inhibited by TGFb. PDGF-induced 
CCND1 expression requiring KLF5 was inhibited by 
TGFb via a Smad dependent mechanism, leading to 
G1 cell cycle arrest of VSMs (Garrido et. al., 2013).  
Neuroectodermal stem cells:  PGE2 (Prostaglandin 
E2) treatment significantly up-regulated CCND1 
(Wong et. al., 2014).  
Neurons:  DYRK1A (dual specificity tyrosine-
phosphorylation-regulated kinase 1A) reduced 
cellular CCND1 levels by phosphorylation on 
Thr286, which is known to induce proteasomal 
degradation (Soppa et. al., 2014).  
Renal intestinal fibroblasts:  Exposure of NRK-
49F to resulted in reduced expression proliferation 
markers CCND1 in a dose and time dependent 
manner (Ponnusamy et. al., 2014).  
Idiopathic pulmonary fibrosis (IPF):  Cell cycle 
regulatory protein CCND1 was significantly 
enhanced in AEC (alveolar epithelial cell) within the 
remodelled fibrotic areas of IPF lungs but expression 
was negligible in myofibroblasts (Akram et. al., 
2014).  
Human Rheumatoid Arthritis Synovial Cells:  
The protein and mRNA levels of CCND1 decreased 
gradually with the increasing of thapsigargin 
concentration and treatment times (Wang et. al., 
2014). 
Other mammals 
Mouse:  
Adult mice cardiomyocytes: Silencing the CCND1 
expression is necessary for the maintenance of the 
cell cycle exit, and suggests a mechanism that 
involves inhibition of M-phase entry (Tane et. al., 
2004).  
Mouse hair follicle (HF): Real-time PCR analysis 
revealed an inverse relationship between CCND1 
expression pattern and that of Sfrp2 throughout the 
HF cycle (Kim et. al., 2014).  
Mouse mammary gland: CCND1 was more 
frequently up-regulated in mammary tumors from 
transgenic mice (expressing myristoylated-Akt1 
(myr-Akt1) under the control of the MMTV-LTR 
promoter) compared to tumors from wild-type mice. 
Increased expression of CCND1 was incompletely 
dependent on Akt1 expression. Low expression of 
CCND1 and increased expression of Twist and Slug 
was observed in mammary tumors that had 
metastasized to secondary sites (Wu et. al., 2014).  
Atherosclerosis in mice: The expression levels of 
CCND1 in smooth muscle cells were restrained by 
CD59 and C-PC (C-phycocyanin) (Li et. al., 2013).  
Mouse pancreatic cancer: Embelin-treated mice 
showed significant inhibition in tumor growth, 
which was associated with reduced expression of 
CCND1 (Huang et. al., 2014).  
Human umbilical cord mesenchymal stem cells 
(hUCMSCs) in nude mice: In mice treated with 
hUCMSCs-LV-IL-21, Expression of cyclin-D1 was 
simultaneously low compared to control group, 
hUCMSCs group and hUCMSCs-LV-Vec group 
(Zhang et. al., 2014).  
Partial hepatectomy: Following seventy percent 
partial hepatectomy (PH) in wild type (WT) mice IL-
6 serum levels increased, resulting in increased 
CCND1 (Tachibana et. al., 2014).  
Cow:  
Dairy Cow Mammary Epithelial Cells: Treatment 
with leucine induced LeuRS, increasing CCND1 
mRNA and protein expression (Wang et. al., 2014).  
Rat:  
Rat epithelial cells: CCND1 accumulation due to 
differential effects of of PKC was likely contribute 
to the opposing tumor suppressive and tumor 
promoting activities in the intestinal epithelium 
(Pyfz et. al., 2014). 
Hyperbilirubinemic Gunn Rat: Decreased 
expression in CCND1 in the cerebellum of the 
hyperbilirubinemic Gunn rats led to significant 
increased cell cycle arrest in the late G0/G1 phase 
(Robert et. al., 2013).  
Neonatal hypoxia-ischemia in rat: IGF-1R 
activation together with EGFR co-signaling 
decreased the percentage of cells in G1 and enhanced 
cell progression into S and G2 by increases in 
expression of CCND1 (Alagappan et. al., 2014).  
Rat balloon injury model: CCND1 mRNA was 
significantly decreased by sodium ferulate in cells 
under serum stimulation (Zhang et. al., 2014).  
Rat liver fibrosis: Sophocarpine inhibited the 
proliferation of HSCs by a decrease in the expression 
of CCND1 (Qian et. al., 2014).  
Rat Airway Smooth Muscle Cells: Nicotine 
significantly increased expression of CCND1 (He et. 
al., 2014). 
Chicken:  
Chicken fetal myoblasts (CFMs): Increased 
CCND1 expression during acceleration of cell cycle 
at G1/ S phase in CMF was due to CARP (cardiac 
ankyrin repeat protein) over-expression (Ma. et. al., 
2014). 
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